摘要
目的探讨乳腺癌复发／转移部位及生存与血清癌抗原15-3（CAl53）、碱性磷酸酶水平（ALP）的关系。方法分析192例晚期乳腺癌患者的血清CAl53、ALP水平。结果血清CAl53、ALP水平的均值及联合检测阳性率与转移部位无明显相关；单纯骨骼／软组织／肝脏／肺脏转移组，CAl53阳性率均高于ALP（52．2％比14．3％、64．4％比7．0％、83．3％比0．0％、69．2％比0．0％），差异有统计学意义（P〈0．05）；不同病理分子分型的CAl53、ALP单独及联合检测阳性率差异无统计学意义（P〉0．05）；CAl53阈值为17U／ml时，阴性组中位无疾病进展时间（PFS）为12．0个月，阳性组为10．0个月，差异有统计学意义（P〈0．05）；ALP水平对PFS无明显影响。结论血清CAl53、ALP水平对乳腺癌复发／转移部位可能有一定的提示意义，与病理分子分型元明显相关，CAl53水平影响晚期乳腺癌患者的生存。
Objective To investigate the association between cancer antigen 15-3 （CA153）, al- kaline phosphatase （ALP） and relapsed/metastatic locations in advanced breast cancer patients and to ana- lyze the effect on survival. Methods The data of CA153 and ALP levels in 192 consecutive patients were examined. Results The mean levels of serum CA153 and ALP were not significantly higher in the different relapsed/me!astatic locations. CA153 and ALP levels were not associated with relapsed/metastatic locations and pathological subtypes. The positive rate of CA153 significantly exceeded that of ALP in the bone, soft tissue, liver and lung metastatic groups （52. 2% vs. 14. 3%, 64.4% vs. 7.0% , 83.3% vs. O. 0%, and 69. 2% vs. 0. 0% , respectively）. Log-Rank analysis revealed that when serum CA153 cut-off value was 17 U/ml, the median progression-free survival （ PFS ） in the negative group and positive group was 12. 0 months and 10. 0 months respectively （P 〈 0.05 ）. Conclusion CA153. and ALP levels may be important in predicting relapsed/metastatic locations in advanced breast cancer patients. CA153 is a useful parameter for predicting clinical outcomes.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2012年第11期2291-2293,共3页
Chinese Journal of Experimental Surgery
关键词
乳腺癌
癌抗原15-3
碱性磷酸酶
复发
转移
Breast carcinoma
Cancer antigen 15-3
Alkaline phosphatase
Recurrence
Metastastatic
